carboxyamidotriazole

also known as CAI · L 651582 · NSC #609974

Developed for: kidney cancer · ovarian cancer · adult glioblastoma · breast cancer · cancer of unknown primary site · central nervous system neoplasm · cutaneous melanoma · fallopian tube cancer
+8 more
· giant cell glioblastoma · gliosarcoma · lung cancer · lymphoma · non-small cell lung carcinoma · peritoneum cancer · renal cell carcinoma · small intestine cancer
Investigated by: National Cancer Institute (NCI) · Eastern Cooperative Oncology Group · National Institutes of Health Clinical Center (CC)

Trials 7 · a red edge is where a trial was stopped

today NCT00006486 · Ph 2 NCT00004146 · Ph 2 NCT00005045 · Ph 2 NCT00003869 · Ph 3 NCT00003249 · Ph 1 NCT00019461 · Ph 2 NCT00019019 · Ph 1

1994199519961997199819992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 12 trials
Phase 1	NCT00003249	May 1998 → Dec 2001	cancer of unknown primary site	National Cancer Institute (NCI)	Completed	No outcome recorded
Phase 1	NCT00019019	Oct 1994 → Jul 2006	breast cancer, central nervous system neoplasm, cutaneous melanoma, kidney cancer +4	National Institutes of Health Clinical Center (CC)	Completed	No outcome recorded
Phase 24 trials
Phase 2	NCT00006486	Oct 2000 → Oct 2005	renal cell carcinoma	National Cancer Institute (NCI)	Completed	No outcome recorded
Phase 2	NCT00004146	Mar 2000 → Jan 2010	adult glioblastoma, giant cell glioblastoma, gliosarcoma	National Cancer Institute (NCI)	Completed	No outcome recorded
Phase 2	NCT00005045	Mar 2000 → Jun 2004	kidney cancer	Eastern Cooperative Oncology Group	Completed	No outcome recorded
Phase 2	NCT00019461	Apr 1998 → Oct 2007	fallopian tube cancer, ovarian cancer, peritoneum cancer	National Cancer Institute (NCI)	Completed	No outcome recorded
Phase 31 trial
Phase 3	NCT00003869	Apr 1999 → May 2008	non-small cell lung carcinoma	National Cancer Institute (NCI)	Completed	No outcome recorded

Evidence & citations 7 cited values

Every value below carries the sentence it was read from. 11 sources stand behind the page.

Field	Value	Cited text
Known as	carboxyamido-triazole	“Preclinical and clinical investigation of the combination of the antiangiogenesis/anti-invasion agent carboxyamido-triazole (CAI) administered with the cytotoxic agent paclitaxel (PAX).” PMID 11410496 ↗ Jun 2001 7 NCT00003249 ↗ NCT00003869 ↗ NCT00005045 ↗ NCT00019019 ↗ NCT00004146 ↗ NCT00006486 ↗ NCT00019461 ↗
Known as	CAI	“BACKGROUND: The current study evaluated the response rate and 6-month time to disease progression of the antiangiogenesis agent carboxyamidotriazole (CAI) in patients with...” PMID 16222691 ↗ Dec 2005 3 “Preclinical and clinical investigation of the combination of the antiangiogenesis/anti-invasion agent carboxyamido-triazole (CAI) administered with the cytotoxic agent paclitaxel (PAX).” PMID 11410496 ↗ Jun 2001 “PURPOSE: Carboxyamidotriazole (CAI) is a cytostatic inhibitor of nonvoltage-operated calcium channels and calcium channel-mediated signaling pathways.” PMID 14645425 ↗ Dec 2003 “Patients receive oral carboxyamidotriazole (CAI) as a test dose on day 1.” NCT00003249 ↗
Known as	L 651582	ChEMBL registry synonym — accepted as the source's own label CHEMBL95431 ↗
Known as	NSC #609974	“Phase II Study of Carboxyamidotriazole (CAI, NSC #609974) in Patients With Advanced Renal Cell Carcinoma Refractory to Immunotherapy” NCT00005045 ↗
Action	Inhibit	“Carboxyamidotriazole (CAI) is a cytostatic inhibitor of nonvoltage-operated calcium channels and calcium channel-mediated signaling pathways.” PMID 14645425 ↗ Dec 2003
Modality	Other / unclassified	“the antiangiogenesis agent carboxyamidotriazole (CAI)” PMID 16222691 ↗ Dec 2005
Route	Oral	“Patients receive oral carboxyamidotriazole (CAI) as a test dose on day 1.” NCT00003249 ↗